I have type 2 diabetes. Are GLP-1 medicines for me?
What Ozempic, Mounjaro and similar medicines do for blood sugar, where they fit in NHS diabetes care, how they work with your other medicines, and what to read next.
They may be. GLP-1 medicines such as semaglutide (Ozempic, Rybelsus) and tirzepatide (Mounjaro) are used on the NHS for type 2 diabetes. They lower HbA1c (a blood test of your average sugar over 2 to 3 months), and often weight. In NHS care they are usually added to your first tablets, such as metformin, not used instead of them. If you also take insulin or a sulfonylurea (an older type of diabetes tablet, such as gliclazide), your doctor may lower that dose to prevent low sugar.
On this page
Where do GLP-1s fit in NHS diabetes care?
Usually as an add-on, not the first medicine. NICE, the body that writes guidance for the NHS in England, updated its type 2 diabetes guideline in February 2026.1
- Heart or blood-vessel disease. If you develop disease caused by narrowed arteries (atherosclerotic cardiovascular disease, such as a heart attack or stroke), NICE says to offer semaglutide (Ozempic) injections, up to 1 mg a week.1
- Living with obesity. NICE says to consider adding a GLP-1 medicine or tirzepatide (Mounjaro) after at least 3 months on your first medicines, if you need more treatment.1
- Diabetes that started young. For early-onset type 2 diabetes, NICE says to consider adding a GLP-1 medicine or tirzepatide.1
Your GP or diabetes team prescribes them. What you pay:
- England. If your diabetes is treated with medicines (not diet alone), you can get a medical exemption certificate, which makes your NHS prescriptions free.3
- Scotland, Wales and Northern Ireland. NHS prescriptions are free for everyone (in Wales, if you're registered with a Welsh GP).4,5,6
What is HbA1c, and how often is it tested?
HbA1c is a common blood test that shows your average blood sugar over the last 2 to 3 months. It's the main number used to track type 2 diabetes.
Sugar in your blood sticks to haemoglobin, the protein in red blood cells. The test measures how much of it has sugar attached. The more sugar in your blood over those months, the higher the number.18 A finger-prick test shows your sugar at one moment. HbA1c is closer to an average over months.2
- The UK unit. UK results are usually given in mmol/mol. Many websites use a percentage instead. For example, 48 mmol/mol is the same as 6.5%, and 53 mmol/mol is the same as 7.0%.1
- No fasting needed. It's a normal blood draw, at any time of day.17
- How often. NICE says every 3 to 6 months until your HbA1c is stable on unchanging treatment, then every 6 months.1
- The diabetes range. An HbA1c of 6.5% (48 mmol/mol) or above is in the diabetes range.17
What HbA1c should I aim for?
NICE's usual target is 48 mmol/mol (6.5%), or 53 mmol/mol (7.0%) if you take a medicine that can cause low sugar. You and your doctor agree yours.
A lower target means less risk of long-term damage, but more risk of low sugar. That's why it differs from person to person.1,2
What two guidelines say:
NICE (England), 2026
- Usual target
- 48 mmol/mol (6.5%) on diet alone or on medicines that don't cause hypos (episodes of low sugar); 53 mmol/mol (7.0%) on a medicine that can cause hypos1
- When it may differ
- It may be relaxed case by case, especially for older or frailer people, people at risk of falls, or people who drive for work1
American Diabetes Association, 2026
NICE is the National Institute for Health and Care Excellence.
How do they compare with metformin, and can I take both?
Metformin is a common first tablet for type 2 diabetes. In a direct comparison, a weekly GLP-1 lowered HbA1c a little more than metformin. The two can also be taken together.
A fall in HbA1c of 1 point means, for example, going from 8% to 7%. The two trials below compared medicines with each other, not with a dummy treatment.
Average fall in HbA1c, in percentage points:
807 people with type 2 diabetes, each on one medicine alone, 26 weeks (about 6 months).10
1,879 people already taking metformin, with an average HbA1c of 8.3% at the start, 40 weeks (about 9 months). People knew which medicine they were on. Paid for by Eli Lilly, the maker of tirzepatide.11
These are averages from two separate trials with different people, so don't compare numbers across the two cards. The Ozempic label reports no new safety problems in 959 people who took it with metformin in trials.12
What if I also take insulin or a sulfonylurea?
Then your risk of low sugar (a hypo) goes up. Your doctor may lower your insulin or sulfonylurea dose when you start.
Sulfonylureas are older tablets such as gliclazide and glimepiride. They can cause hypos on their own.1 The Ozempic label warns that combining them can cause hypos, including severe ones.12 A lower sulfonylurea or insulin dose may reduce that risk.12 That's your doctor's call, so don't change doses yourself.
Signs of low sugar include:12
- dizziness, shaking or sweating
- hunger
- blurred vision
- a fast heartbeat
- confusion or drowsiness
What about my kidneys and eyes?
For kidneys, one large trial found fewer serious kidney problems on semaglutide in people who already had kidney disease. For eyes, tell whoever checks your eyes that you've started, especially if you have retinopathy (damage to the back of the eye from diabetes).
A large kidney trial followed 3,533 people who had type 2 diabetes and kidney disease, for about 3.4 years. Half took semaglutide (Ozempic) 1 mg a week, half a dummy injection with no medicine in it.13
The researchers counted everyone who had any one of these:13
- kidney failure: needing dialysis or a transplant, or kidney function falling very low
- losing at least half of their kidney function
- dying from kidney or heart causes
Out of every 100 people, how many had one or more of these:
3,533 people with type 2 diabetes and kidney disease, about 3.4 years.13
So about 4 or 5 fewer in 100 had one of these on semaglutide.
What this means. Semaglutide lowered the risk of these events by about a quarter (24%).13 Put simply: for every 22 people treated for about 3 years, one fewer person had kidney failure, a big loss of kidney function, or died from kidney or heart causes. The difference was clear enough that the trial was stopped early.13 This was in people who already had kidney disease, so it doesn't show the medicine protects healthy kidneys.
But vomiting or diarrhoea can dry you out, and that can damage the kidneys.12
Eyes. In a 2-year trial in people with type 2 diabetes, eye complications from retinopathy were more common on Ozempic than on a dummy injection. The gap was bigger in people who already had retinopathy.12
Out of every 100 people, how many had eye complications:
A 2-year trial in people with type 2 diabetes.12
Everyone in the trial
People who already had retinopathy
Bars for eyes are drawn on a scale up to 10 in 100.
Report any change in your vision.12
Will I lose as much weight as people without diabetes?
On average, people with diabetes lost less in trials. Two trials of semaglutide 2.4 mg, the weekly dose sold as Wegovy, each ran for 68 weeks (about 16 months).
Average share of body weight lost, and what that means for someone who starts at 90 kg (14 st 2 lb):
1,210 adults with type 2 diabetes and overweight or obesity, 68 weeks.14
1,961 adults with overweight or obesity and no diabetes, 68 weeks.15
What this means. These are separate trials with different people, so the gap between them is a rough guide, not a direct comparison. They are averages too, so your own result may be higher or lower.
Questions to take to your GP or diabetes nurse
- What is my HbA1c target in mmol/mol, and why?
- Should my gliclazide or insulin dose change if I start?
- Do I need an eye check first?
- In England: do I have a medical exemption certificate for my prescriptions?
What to read next, in order
These four guides go deeper. Each one ends with a link to the next, so you can read them one after another.
- 1Weight and health: what BMI and waist numbers meanHow weight links to diabetes, and why NICE uses lower BMI thresholds for some ethnic groups.
- 2What do GLP-1 medicines do?How these medicines release insulin only when sugar is high.
- 3Side effects and risksStomach effects, and the risks that matter more with diabetes.
- 4Getting a prescription in the UKThe UK brands licensed for diabetes, who prescribes them, and what you pay in each nation.
Sources
- NICE. Type 2 diabetes in adults: management. NICE guideline NG28, last updated 18 February 2026. Recommendations 1.5.1–1.5.9 (HbA1c measurement and targets), and the sections on initial medicines and further medication. Link
- American Diabetes Association. 6. Glycemic goals, hypoglycemia, and hyperglycemic crises: Standards of Care in Diabetes 2026. Diabetes Care, 2026;49(Suppl 1):S132. Recommendations 6.2, 6.3a, 6.4. Declared interests: 2 of 20 committee members declare consulting, advisory or grant ties to Novo Nordisk and 1 to Eli Lilly; 5 of 22 invited subject experts declare ties to each (ADA's own 2026 disclosure list). Full text
- NHS Business Services Authority. Medical exemption certificates (covers "diabetes mellitus, except where treatment is by diet alone"). Checked 12 October 2026. Link
- NHS inform (Scotland). Prescriptions ("Prescriptions in Scotland are free"). Checked 12 October 2026. Link
- Welsh Government. Free prescriptions ("If you are registered with a GP in Wales you are entitled to free prescriptions from a pharmacist in Wales"). Checked 12 October 2026. Link
- nidirect (Northern Ireland). Help with health costs ("All prescriptions dispensed in Northern Ireland are free of charge for everyone"). Checked 12 October 2026. Link
- MHRA. GLP-1 medicines for weight loss and diabetes: what you need to know. GOV.UK, updated 5 February 2026. Licensed-use table, and how long to stop before trying to get pregnant. Link
- Eli Lilly. Mounjaro KwikPen, UK summary of product characteristics (SmPC), section 4.1. Electronic Medicines Compendium, revised 29 August 2026. Link
- Diabetes UK. Our response to serious supply issues of drugs for people living with type 2 diabetes ("At the end of January in 2025 it was reported that the shortages of GLP-1 medications had been resolved"). Updated 20 October 2025. Link
- Umpierrez G et al. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes (AWARD-3). Diabetes Care, 2014;37(8):2168–2176. 807 people, 26 weeks. DOI
- Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). NEJM, 2021;385:503–515. All participants were on metformin (ClinicalTrials.gov NCT03987919). DOI
- Novo Nordisk. Ozempic (semaglutide) injection, US prescribing information and Medication Guide, revised May 2026. Sections 4, 5.3, 5.5, 5.6, 7.2, 8.5. (US label.) PDF
- Perkovic V et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). NEJM, 2024;391:109–121. 3,533 people, median 3.4 years. DOI
- Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet, 2021;397:971–984. DOI
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM, 2021;384:989–1002. 1,961 adults without diabetes, 68 weeks. DOI
- Novo Nordisk. Wegovy (semaglutide) US prescribing information, revised June 2026. Sections 1, 2.2, 5.2, 5.3, 5.5, 8.3, 17. (US label.) PDF
- American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: Standards of Care in Diabetes 2026. Diabetes Care, 2026;49(Suppl 1):S27–S49. Tables 2.1–2.3. DOI
- Nathan DM et al. Translating the A1C assay into estimated average glucose values (ADAG). Diabetes Care, 2008;31(8):1473–1478. 507 people. DOI
- NHS. When to use 111 (England); NHS 24 (Scotland) and NHS 111 Wales run the 111 service in those nations; Northern Ireland has no 111 service, so callers contact their GP surgery for out-of-hours care. Checked 12 October 2026. Link
- MHRA. Yellow Card scheme: report a side effect online or in the Yellow Card app. Link
Last checked 12 Oct 2026 · Next review due Jan 2027
How this page was made. Written by the GLP Guidebook team from the sources above: drug labels, published trials, NICE and international guidelines, and official NHS and MHRA pages. It's general information, not medical advice. Talk to your GP, diabetes team or another qualified prescriber before starting, stopping or changing any medicine. How we write